Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M

CASTLE BIOSCIENCES INC

2023-FY EPS reported -$2.14 revenue$219,788,000

Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.
Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.
TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.
2024 revenue guidance: $235-240 million; management cites strong commercial momentum.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CASTLE BIOSCIENCES INC reported the fourth quarter and year ended December 31, 2023 results: revenue $219.8 million, net income $57.5 million.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $219.8 million
Net income: $57.5 million
Result: reported results

Exact text from the filing

in such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.